Is MRD testing ready for “prime time”?

Submitted by blackswan on Fri, 07/15/2016 - 01:17

The answer is a definite yes and no! Yes, it is now a priority to test for minimal residual disease (MRD) in myeloma clinical trials. However, no, MRD testing is not yet recommended in routine clinical practice.  But I’m pleased to report that we are getting there.

MRD testing in myeloma takes center stage

Submitted by blackswan on Thu, 11/12/2015 - 22:43

Last week’s 4th Annual ESLHO (European Scientific foundation of Laboratory Hemato Oncology) Symposium in Zurich, Switzerland was the first ever dedicated exclusively to examining “New Developments in MRD Diagnostics.” The two-day event provided a comprehensive review of the current status of MRD (minimal residual disease) testing and future optio